Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 29:9:2027-32.
doi: 10.2147/OPTH.S90979. eCollection 2015.

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity

Odalis Arámbulo  1 , Gabriel Dib  1 , Juan Iturralde  1 , Fahir Duran  1 , Miguel Brito  1 , João B Fortes Filho  2
Affiliations

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity

Odalis Arámbulo et al. Clin Ophthalmol. .

Abstract

Purpose: The aim of the study was to assess the outcomes of severe retinopathy of prematurity (ROP) in zone I or posterior zone II treated with intravitreal ranibizumab (IVR) as monotherapy or combined treatment with laser photocoagulation.

Methods: This is a retrospective study analyzing clinical records of the included patients. Patients were divided into two groups: group 1 included patients who received only IVR treatment; and group 2 was subdivided into group 2A - including patients with IVR as initial treatment and complementary laser photocoagulation if retinal neovascularization or plus disease did not regress, and group 2B - including patients with initial laser photocoagulation and IVR as rescue therapy. Favorable outcomes were regression of the retinal neovascularization and plus disease, meaning control of the disease. Unfavorable outcomes were progression to stages 4 and 5 of ROP.

Results: Fifty-seven eyes were included in the study. Mean birth weight and gestational age were 1,281±254 g and 29.5±2.1 weeks, respectively. Group 1 comprised of 16 eyes, with favorable outcomes in 14 eyes (87.5%). Group 2 comprised of 41 eyes, with favorable outcomes in 29 eyes (70.7%), in a mean follow-up period of 12.8 months.

Conclusion: IVR was effective to treat severe cases of ROP as a primary or a combined treatment. Forty-three of the 57 treated eyes (75.4%) achieved regression of ROP and favorable outcomes.

Keywords: VEGF; aggressive posterior ROP; bevacizumab; prematurity; ranibizumab; retinopathy of prematurity; therapy; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Image before IVR monotherapy (A); 6 days after IVR monotherapy (B); and after 6 months of IVR monotherapy (C). Abbreviation: IVR, intravitreal ranibizumab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Committee for the Classification of Retinopathy of Prematurity The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991–999. - PubMed
    1. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina. 2006;26(7 suppl):S11–S15. - PubMed
    1. Yokoi T, Hiraoka M, Miyamoto M, et al. Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology. 2009;116(7):1377–1382. - PubMed
    1. Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina. 2009;29(9):1335–1339. - PubMed
    1. Multicenter trial of cryotherapy for retinopathy of prematurity Preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1988;106(4):471–479. - PubMed